Trial Profile
A randomized study of observation versus adjuvant low-dose extended duration interferon alpha-2A in completely resected high-risk malignant melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon alpha (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms AIM-HIGH